Selected publications
For complete publication list, visit NCBI - https://www.ncbi.nlm.nih.gov/myncbi/dennis.watson.1/bibliography/public/
-
Lathia JD, Watson DC. "Dose Determination and Administration of Bacterial Extracellular Vesicles for In Vivo Preclinical Studies.” Chapter in: Bacterial Extracellular Vesicles, Methods in Molecular Biology, 2843 (2024):219-37
-
Karaman I, Pathak A, Bayik D, Watson DC. “Harnessing bacterial extracellular vesicle immune effects for cancer therapy.” Pathogens and Immunity, [Review], 9.1 (2024): 56-90
​​​
-
Teran Pumar O, Lathia JD, Watson DC*, Bayik D*. “’Slicing’ glioblastoma drivers with the Swiss cheese model.” Trends in Cancer, [Review], 10.1 (2024). 15-27. [Cover featured article]
​​
-
Welsh JA….MISEV Consortium [including Watson DC], Thery C, Witwer KW. “Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches.” J Extracellular Vesicles. 13.2 (2024):e12404. [International Society guidelines]
​
Past relevant work
​
-
Watson DC*, Bayik D*, Storevik S*, Moreino SS*, Sprowls SA, [and 35 others], Miletic H, Lathia JD. “GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity.” Nature Cancer, 4.5 (2023), 648-64. [Cover featured article]
--Featured 2023 highlights of Nature Cancer publications: https://www.nature.com/collections/bcggjhfcea
​
-
Conlon KC*, Watson DC*, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter L, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh N, Long D, Kurtulus S, Lee LH, Chowdhury NR, Bender FL, Pavlakis GN. “A phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 (hetIL-15) agonist, in adult patients with metastatic or unresectable solid tumors.” J Immunother Cancer, 9.11 (2021): e003388.
​
-
Watson DC, Moysi E, Valentin A, Bergamaschi C, Devasundaram S, Fortis SP, Bear J, Chertova E, Bess Jr. J, Sowder R, Venzon DJ, Deleage C, Estes JD, Lifson JD, Petrovas C, Felber BK, Pavlakis GN. “Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes.” PLoS Pathogens, 14 (2018): e1006902.
​
-
Watson DC, Yung BC, Bergamaschi C, Chowdhury B, Bear J, Stellas D, Morales-Kastresana A, Jones JC, Felber BK, Chen X, Pavlakis GN. “Scalable, cGMP-compatible purification of extracellular vesicles carrying human, bioactive heterodimeric IL-15 / Lactadherin complexes.” J Extracellular Vesicles, 7 (2018): 1442088.
​
-
Watson DC, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M, Morales-Kastresana A, Jones JC, Felber BK, Chen X, Gursel I, Pavlakis GN. “Efficient Production and Enhanced Tumor Delivery of Engineered Extracellular Vesicles.” Biomaterials, 105(2016):195-205.